摘要
目的探讨维格列汀联合二甲双胍治疗2型糖尿病的临床疗效及对慢性炎症状态的影响。方法选取2013年7月至2014年9月医院收治的2型糖尿病患者130例,随机分为观察组和对照组,各65例。对照组患者采用二甲双胍治疗,观察组在此基础上加用维格列汀,均持续治疗10周。结果治疗后,观察组患者总有效率为96.92%,高于对照组的86.15%(P<0.05);与治疗前比较,两组患者炎症因子肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)水平均显著下降(P<0.05),且观察组低于对照组(P<0.05)。观察组腹部不适发生率高于对照组(P<0.05);恶心、低血糖发生率与对照组相当(P>0.05)。结论 2型糖尿病患者在接受二甲双胍治疗基础上加用维格列汀可更有效地控制血糖,减轻炎性反应,改善胰岛素抵抗,不良反应轻。
Objective To explore the efficacy of vildagliptin in treating patients with type 2 diabetes and its influence on chronic inflammatory state. Methods 130 patients with type 2 diabetes from July 2013 to September 2014 were randomly divided into observation group and control group. The control group received metformin treatment, the observation group was added with vildagliptin. The two groups were both treated of 10 weeks. Results After treatment,the total effective rate of the observation group was 96. 92%,which was obviously higher than 86. 15 % of the control group（ P 〈 0. 05）; compared with before treatment, the CRP, IL- 6 and TNF- αexpression levels of the two groups were significantly decreased（ P 〈 0. 05）,and the decrease in the observation group was more obvious（ P 〈 0. 05）; the incidence rate of abdominal discomfort in the observation group was higher than the control group（ P 〈 0. 05）,which the incidence rate of nausea and hypoglycemia was similar to the control group（ P 〉 0. 05）. Conclusion Vildagliptin combined with metformin in treating patients with type 2 diabetes can effectively control blood sugar,reduce the inflammatory response,improve the insulin resistance,with less severe adverse reactions.
出处
《中国药业》
CAS
2015年第23期31-32,共2页
China Pharmaceuticals
